Skip to main content

Genómica psiquiátrica

FJC2021-047538-I

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Desarrollar, Atraer y Retener Talento
Subprogram Subprograma Estatal de Formación
Call Juan de la Cierva Formación
Call year 2021
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The genomics of visuospatial neurocognition in obsessive-compulsive disorder: A preliminary GWAS

  • Alemany-Navarro, María
  • Tubío-Fungueiriño, María
  • Diz-de Almeida, Silvia
  • Cruz, Raquel
  • Lombroso, Adam
  • Real, Eva
  • Soria, Virginia
  • Bertolin, Sara
  • Fernández-Prieto, Montse
  • Alonso, Pino
  • Menchón, José M.
  • Carracedo, Ángel
  • Segalàs, Cinto
© 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)., [Background] The study of Obsessive-Compulsive Disorder (OCD) genomics has primarily been tackled by Genome-wide association studies (GWAS), which have encountered troubles in identifying replicable single nucleotide polymorphisms (SNPs). Endophenotypes have emerged as a promising avenue of study in trying to elucidate the genomic bases of complex traits such as OCD., [Methods] We analyzed the association of SNPs across the whole genome with the construction of visuospatial information and executive performance through four neurocognitive variables assessed by the Rey-Osterrieth Complex Figure Test (ROCFT) in a sample of 133 OCD probands. Analyses were performed at SNP- and gene-level., [Results] No SNP reached genome-wide significance, although there was one SNP almost reaching significant association with copy organization (rs60360940; P = 9.98E-08). Suggestive signals were found for the four variables at both SNP- (P < 1E-05) and gene-levels (P < 1E-04). Most of the suggestive signals pointed to genes and genomic regions previously associated with neurological function and neuropsychological traits., [Limitations] Our main limitations were the sample size, which was limited to identify associated signals at a genome-wide level, and the composition of the sample, more representative of rather severe OCD cases than a population-based OCD sample with a broad severity spectrum., [Conclusions] Our results suggest that studying neurocognitive variables in GWAS would be more informative on the genetic basis of OCD than the classical case/control GWAS, facilitating the genetic characterization of OCD and its different clinical profiles, the development of individualized treatment approaches, and the improvement of prognosis and treatment response., This work was supported by Carlos III Health Institute (PI16/00950, PI16/00950, PI22/00752); FEDER funds (‘A way to build Europe’), and CERCA Programme / Generalitat de Catalunya. MA was supported by a Juan de la Cierva contract (FJC2021-047538-I)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Efficacy of clozapine versus standard treatment in adult individuals with intellectual disability and treatment-resistant psychosis (CLOZAID): study protocol of a multicenter randomized clinical trial

  • Alemany-Navarro, María
  • Sánchez-Barbero, Bianca
  • Reguera-Pozuelo, Pablo
  • Altea-Manzano, Laura
  • Gómez-Garrido, Ana
  • Rocha-González, Idalino
  • Garrido-Torres, Nathalia
  • Ruiz‐Veguilla, Miguel
  • García-Cerro, Susana
  • Rosso-Fernández, Clara M.
  • Villagrán-Moreno, José María
  • Sarramea, Fernando
  • Cervilla-Ballesteros, Jorge
  • Martínez-Leal, Rafael
  • Mayoral-Cleries, Fermín
  • Crespo-Facorro, Benedicto
Intellectual disability (ID) affects approximately 1% of the worldwide population and individuals with ID have a higher comorbidity with mental illness, and specifically psychotic disorders. Unfortunately, among individuals with ID, limited research has been conducted since ID individuals are usually excluded from mental illness epidemiological studies and clinical trials. Here we perform a clinical trial to investigate the effectiveness of clozapine in the treatment of resistant psychosis in individuals with ID. The article highlights the complexity of diagnosing and treating psychopathological alterations associated with ID and advocates for more rigorous research in this field., This study has been funded by Instituto de Salud Carlos III through the project "ICI19/00026" (Co-funded by European Regional Development Fund/European Social Fund; “A way to make Europe”/"Investing in your future"). Prof. BC-F has received unrestricted research funding from Carlos III Health Institute, MINECO, Gobierno de Cantabria, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), from the 7th European Union Framework Program and Lundbeck. He has also received honoraria for his participation as a consultant and/or as a speaker at educational events from Janssen Cilag, Rovi, Angelini, Boehringer, Mylan, Lundbeck, and Otsuka Pharmaceuticals. MA-N was supported by a Juan de la Cierva contract (FJC2021-047538-I)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring genetic testing requests, genetic alterations and clinical associations in a cohort of children with autism spectrum disorder

  • Garrido-Torres, Nathalia
  • Marqués Rodríguez, Renata
  • Alemany-Navarro, María
  • Sánchez-García, Javier
  • García-Cerro, Susana
  • Ayuso, María Irene
  • González-Meneses, Antonio
  • Martínez Mir, Amalia
  • Ruiz‐Veguilla, Miguel
  • Crespo-Facorro, Benedicto
Several studies show great heterogeneity in the type of genetic test requested and in the clinicopathological characteristics of patients with ASD. The following study aims, firstly, to explore the factors that might influence professionals' decisions about the appropriateness of requesting genetic testing for their patients with ASD and, secondly, to determine the prevalence of genetic alterations in a representative sample of children with a diagnosis of ASD. Methods: We studied the clinical factors associated with the request for genetic testing in a sample of 440 children with ASD and the clinical factors of present genetic alterations. Even though the main guidelines recommend genetic testing all children with an ASD diagnosis, only 56% of children with an ASD diagnosis were genetically tested. The prevalence of genetic alterations was 17.5%. These alterations were more often associated with intellectual disability and dysmorphic features. There are no objective data to explicitly justify the request for genetic testing, nor are there objective data to justify requesting one genetic study versus multiple studies. Remarkably, only 28% of males were genetically tested with the recommended tests (fragile X and CMA). Children with dysmorphic features and organic comorbidities were more likely to be genetic tested than those without. Previous diagnosis of ASD (family history of ASD) and attendance at specialist services were also associated with Genetically tested Autism Spectrum Disorder GTASD. Our findings emphasize the importance of establishing algorithms to facilitate targeted genetic consultation for individuals with ASD who are likely to benefit, considering clinical phenotypes, efficiency, ethics, and benefits., NG-T received funds under Juan Rodes Contract (JR22/00075), with the Carlos III Health Institute. SG-C received funds under Sara Borrell contract (CD19_00183) with the Carlos III Health Institute. María Alemany received funds under Juan de la Cierva Contract (FJC2021-047538-I). This study was approved by the local institutional review board (the Clinical Research Ethics Committee of Andalusia) in accordance with international research ethics standards. Funding for open access publishing: Universidad de Sevilla/CBUA., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Impact of maternal stress and COVID-19 exposure during pregnancy on offspring neurodevelopment: signature cohort 12 month follow-up

  • Garrido-Torres, Nathalia
  • Román-Jarrín, Andrés
  • Rider, Julia
  • Alemany-Navarro, María
  • Gibson, Blake A.
  • de-Felipe, Bea
  • Pérez-Gómez, Alberto
  • Cerrillos, Lucas
  • Duque-Sánchez, Cristina
  • Alameda, Luis
  • Ruiz-Mateos, Ezequiel
  • Ruiz-Veguilla, Miguel
  • Crespo-Facorro, Benedicto
The COVID-19 pandemic brought unprecedented global challenges. Amid the crisis, the potential impact of COVID-19 exposure on the neurodevelopment of offspring born to infected mothers emerged as a critical concern. This is a prospective cohort study of pregnant women and their offspring enrolled in the Signature project at Hospital Universitario Virgen del Rocio in Seville, Spain, between 01/01/2024 and 08/31/2022. Participants were subsequently classified into SARS-CoV-2 exposed (mild or severe COVID-19) and non-exposed groups. Maternal stress was assessed through the Perceived Stress Scale; offspring neurodevelopment was screened through Ages & Stages Questionnaire, 3rd Edition (ASQ-3) at 6 months and 12 months. Association between COVID-19 severity and neurodevelopmental outcomes were analyzed with univariate and multivariate analysis. The cohort included 689 women categorized into three distinct groups based on COVID-19 severity: non-infected mothers (N = 277), mothers with mild COVID-19 (N = 358), and mothers with severe COVID-19 (N = 54). The reference category for the odds ratio (OR) analyses was the non-infected group. In utero exposure to mild or severe COVID-19, as well as maternal stress, was not significantly associated with risk of developmental concern in any ASQ-3 subdomain at 12-month follow-up. This study highlights the need for further research with longer follow-up periods to better understand the potential long-term impact of prenatal COVID-19 exposure on offspring neurodevelopment., Dr. Nathalia Garrido-Torres received funds under Juan Rodes Contract (JR22/00075). Dr. María Alemany-Navarro received funds under Juan de la Cierva Contract (FJC2021-047538-I). Dr. Luis Alameda thanks the Foundation Adrian and Simone Frutiger and Carigest SA Foundation for their support. Dr. Andrés Román-Jarrín received funds under Alicia Koplowitz Foundation research grant. Dr. Miguel Ruiz-Veguilla received funds from Carlos III Health Institute. Grant ID: PI22-0678. This work has received funds from the Consejería de Salud y Familias para financiación de la investigación, desarrollo e innovación en ciencias de la salud de Andalucía (CSyF 2021-FEDER), grant number PECOVID -01952020; and also received support from the Alicia Koplowitz Foundation., Peer reviewed